FDA warned PLZ Corp over an OTC talc drug made in Mississauga without asbestos testing and with deficient component controls.
What happened
FDA reviewed records PLZ Corp submitted after FDA's September 8, 2025 request for records under section 704(a)(4) of the FD&C Act. FDA found the firm did not test incoming talc for asbestos, relied on supplier certificates of analysis without establishing their reliability, and used incomplete identity testing for talc. The firm later stated it discontinued the talc-containing drug product, and FDA also found deficient talc specifications and quality-unit oversight.
What FDA found
The firm did not test incoming talc for asbestos and did not establish that its supplier's asbestos test results were reliable.
21 CFR 211.84(d)(1) and (2)The firm's identity testing for talc was incomplete because it lacked USP identification B and C.
21 CFR 211.84(d)(1) and (2)The firm's talc specifications were incomplete: they lacked assay, several impurity limits, and an asbestos test.
21 CFR 211.160(b)The quality unit approved talc for drug manufacturing despite deficient specifications and did not ensure scientifically sound test procedures.
21 CFR 211.22; 21 CFR 211.160(b)
What FDA wants
Respond in writing within 15 working days describing corrections; provide talc retain test results or finished-product asbestos testing within 30 calendar days, and include the requested risk assessment, specification gap analysis, and COA validation plan.
Who should pay attention
- makers of OTC drugs that use talc
- brands relying on supplier certificates of analysis for drug components
- buyers of OTC drug products made at this facility
This is a summary. Read the original letter on fda.gov.